MINNEAPOLIS, November 1, 2022 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2022. The quarterly dividend will be payable November 28, 2022to all ordinary shareholders registered on the November 14, 2022. Future cash dividends will be reviewed by the Board of Directors on a quarterly basis.

Bio-Techne also announced today that its Board of Directors has approved and declared a four-for-one stock split of Bio-Techne common stock in the form of a stock dividend to make stock ownership more accessible to employees and investors. Each shareholder registered in the November 14, 2022 will receive a dividend of three additional common shares for each share then held, to be distributed after the close of trading on November 29, 2022. Trading will commence on a stock split-adjusted basis on November 30, 2022.

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company that provides innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products facilitate scientific research into biological processes as well as the nature and evolution of specific diseases. They contribute to drug discovery efforts and provide the means to perform accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne has generated approximately $1.1 billion of net sales in fiscal year 2022 and has approximately 3,000 employees worldwide. For more information about Bio-Techne and its brands, please visit

Forward-looking statements:

Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect actual results of operations. Forward-looking statements in this press release include statements regarding the potential future repurchase of common stock of Bio-Techne. The following important factors, among others, have affected and in the future may affect the actual results and future share price of the Company: the effect of new branding and marketing initiatives, the integration of new businesses and new leaders, the introduction and acceptance of new products, the funding and direction of types of research by the Company’s customers, the impact of the growing number of producers of biotechnology research products and the associated price competition, general economic conditions, customer site closures or supply chain issues resulting from the COVID-19 pandemic, the impact of exchange rate fluctuations, and the costs and results of efforts research and development of the Company’s products and the companies in which the Company has invested or with which it has established strategic relationships.

For more information about these factors, see the section titled “Risk Factors” in the company’s annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases as a result of new information or future events. Investors are cautioned not to place undue importance on these statements.

SOURCE Bio-Techne Corporation

About Janet Young

Check Also

New Mexico residents owed millions in unclaimed money

A few years ago, I received an urgent email from my sister. The subject line …